Silexion Therapeutics Partners with AMS for Clinical Trials

Silexion Therapeutics ( (SLXN) ) has issued an update.

On September 4, 2025, Silexion Therapeutics announced the selection of AMS Advanced Medical Services GmbH as the contract research organization to support its upcoming Phase 2/3 clinical trials for SIL204, targeting KRAS-driven solid tumors. This partnership, leveraging AMS’s extensive oncology expertise, is a critical step in advancing SIL204, which has shown promising preclinical results, towards clinical development. The trials are expected to commence in the first half of 2026, following regulatory submissions in late 2025 and early 2026.

The most recent analyst rating on (SLXN) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Spark’s Take on SLXN Stock

According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.

Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.

To see Spark’s full report on SLXN stock, click here.

More about Silexion Therapeutics

Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers. The company is dedicated to creating innovative treatments for solid tumor cancers with mutated KRAS oncogenes, which are common oncogenic drivers in human cancers.

Average Trading Volume: 70,735

Technical Sentiment Signal: Sell

Current Market Cap: $5.28M

For detailed information about SLXN stock, go to TipRanks’ Stock Analysis page.